Cardiovascular diseases - improved prediction, prevention, diagnosis, and monitoring

Stage 1 Deadline:

September 20, 2022

Stage 2 Deadline:

February 28, 2023

Project types:

  1. HORIZON-JU-RIA HORIZON JU Research and Innovation Actions

Project Proposal

The call HORIZON-JU-IHI-2022-02-01 has been scheduled to close, so this opportunity is no longer current.

We would like to join a consortium preparing a phase 2 proposal on this topic.

Read bellow the expertise of the interdisciplinary research group of researchers from the Department of Pharmacology and Toxicology, Department of Biophysics and Physical Chemistry and Department of Pharmaceutical Technology.

Our group is mainly involved in research of molecular aspects of pharmacokinetics and gene regulation via nuclear receptors, development of novel nuclear receptor ligands or their nanoformulation for targeted delivery of inflammatory diseases of the liver and the gut, in mathematical modeling and pharmacometrics, and radiopharmacy.

Our group works on the following topics:
• Development of novel nuclear receptor ligands for the treatment of inflammatory liver diseases (Non-alcoholic fatty liver disease (NAFLD) or inflammatory bowel disease)
• Development of novel nanoformulations for targeted delivery of the diseases
• The study of xenobiotic and endobiotic metabolism regulation via nuclear receptors
• Mathematical modeling of drug effects, pharmacometrics and in silico docking
• Development of novel radiopharmaceuticals


Contact: [email protected]

Team leader: Prof. Petr Pávek, PharmDr., Ph.D. ([email protected])